Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis

Treatment selection for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma requires consideration of patient-, disease-, and treatment-related factors, said Tomer Mark, MD, who added that the need for minimal residual disease (MRD) as a surrogate end point for survival is stronger now with optimal sequencing strategies remaining uncertain.